The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Formulation CDMO Services Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule CDMO
1.2.3 Macro-molecular CDMO
1.3 Market by Application
1.3.1 Global Formulation CDMO Services Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinical Application
1.3.3 Commercial Production
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Formulation CDMO Services Market Perspective (2018-2029)
2.2 Formulation CDMO Services Growth Trends by Region
2.2.1 Global Formulation CDMO Services Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Formulation CDMO Services Historic Market Size by Region (2018-2023)
2.2.3 Formulation CDMO Services Forecasted Market Size by Region (2024-2029)
2.3 Formulation CDMO Services Market Dynamics
2.3.1 Formulation CDMO Services Industry Trends
2.3.2 Formulation CDMO Services Market Drivers
2.3.3 Formulation CDMO Services Market Challenges
2.3.4 Formulation CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Formulation CDMO Services Players by Revenue
3.1.1 Global Top Formulation CDMO Services Players by Revenue (2018-2023)
3.1.2 Global Formulation CDMO Services Revenue Market Share by Players (2018-2023)
3.2 Global Formulation CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Formulation CDMO Services Revenue
3.4 Global Formulation CDMO Services Market Concentration Ratio
3.4.1 Global Formulation CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Formulation CDMO Services Revenue in 2022
3.5 Formulation CDMO Services Key Players Head office and Area Served
3.6 Key Players Formulation CDMO Services Product Solution and Service
3.7 Date of Enter into Formulation CDMO Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Formulation CDMO Services Breakdown Data by Type
4.1 Global Formulation CDMO Services Historic Market Size by Type (2018-2023)
4.2 Global Formulation CDMO Services Forecasted Market Size by Type (2024-2029)
5 Formulation CDMO Services Breakdown Data by Application
5.1 Global Formulation CDMO Services Historic Market Size by Application (2018-2023)
5.2 Global Formulation CDMO Services Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Formulation CDMO Services Market Size (2018-2029)
6.2 North America Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Formulation CDMO Services Market Size by Country (2018-2023)
6.4 North America Formulation CDMO Services Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Formulation CDMO Services Market Size (2018-2029)
7.2 Europe Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Formulation CDMO Services Market Size by Country (2018-2023)
7.4 Europe Formulation CDMO Services Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Formulation CDMO Services Market Size (2018-2029)
8.2 Asia-Pacific Formulation CDMO Services Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Formulation CDMO Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Formulation CDMO Services Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Formulation CDMO Services Market Size (2018-2029)
9.2 Latin America Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Formulation CDMO Services Market Size by Country (2018-2023)
9.4 Latin America Formulation CDMO Services Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Formulation CDMO Services Market Size (2018-2029)
10.2 Middle East & Africa Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Formulation CDMO Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Formulation CDMO Services Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medicilon
11.1.1 Medicilon Company Detail
11.1.2 Medicilon Business Overview
11.1.3 Medicilon Formulation CDMO Services Introduction
11.1.4 Medicilon Revenue in Formulation CDMO Services Business (2018-2023)
11.1.5 Medicilon Recent Development
11.2 Gliead
11.2.1 Gliead Company Detail
11.2.2 Gliead Business Overview
11.2.3 Gliead Formulation CDMO Services Introduction
11.2.4 Gliead Revenue in Formulation CDMO Services Business (2018-2023)
11.2.5 Gliead Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Formulation CDMO Services Introduction
11.3.4 Boehringer Ingelheim Revenue in Formulation CDMO Services Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Formulation CDMO Services Introduction
11.4.4 Vertex Revenue in Formulation CDMO Services Business (2018-2023)
11.4.5 Vertex Recent Development
11.5 Mirati Therapeutics
11.5.1 Mirati Therapeutics Company Detail
11.5.2 Mirati Therapeutics Business Overview
11.5.3 Mirati Therapeutics Formulation CDMO Services Introduction
11.5.4 Mirati Therapeutics Revenue in Formulation CDMO Services Business (2018-2023)
11.5.5 Mirati Therapeutics Recent Development
11.6 AMPAC
11.6.1 AMPAC Company Detail
11.6.2 AMPAC Business Overview
11.6.3 AMPAC Formulation CDMO Services Introduction
11.6.4 AMPAC Revenue in Formulation CDMO Services Business (2018-2023)
11.6.5 AMPAC Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Formulation CDMO Services Introduction
11.7.4 Pfizer Revenue in Formulation CDMO Services Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Polypeptide
11.8.1 Polypeptide Company Detail
11.8.2 Polypeptide Business Overview
11.8.3 Polypeptide Formulation CDMO Services Introduction
11.8.4 Polypeptide Revenue in Formulation CDMO Services Business (2018-2023)
11.8.5 Polypeptide Recent Development
11.9 Bachem
11.9.1 Bachem Company Detail
11.9.2 Bachem Business Overview
11.9.3 Bachem Formulation CDMO Services Introduction
11.9.4 Bachem Revenue in Formulation CDMO Services Business (2018-2023)
11.9.5 Bachem Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Formulation CDMO Services Introduction
11.10.4 Merck Revenue in Formulation CDMO Services Business (2018-2023)
11.10.5 Merck Recent Development
11.11 Asymchem
11.11.1 Asymchem Company Detail
11.11.2 Asymchem Business Overview
11.11.3 Asymchem Formulation CDMO Services Introduction
11.11.4 Asymchem Revenue in Formulation CDMO Services Business (2018-2023)
11.11.5 Asymchem Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Formulation CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Sinopep
11.13.1 Sinopep Company Detail
11.13.2 Sinopep Business Overview
11.13.3 Sinopep Formulation CDMO Services Introduction
11.13.4 Sinopep Revenue in Formulation CDMO Services Business (2018-2023)
11.13.5 Sinopep Recent Development
11.14 Frontier Biotechnologies
11.14.1 Frontier Biotechnologies Company Detail
11.14.2 Frontier Biotechnologies Business Overview
11.14.3 Frontier Biotechnologies Formulation CDMO Services Introduction
11.14.4 Frontier Biotechnologies Revenue in Formulation CDMO Services Business (2018-2023)
11.14.5 Frontier Biotechnologies Recent Development
11.15 JYMed
11.15.1 JYMed Company Detail
11.15.2 JYMed Business Overview
11.15.3 JYMed Formulation CDMO Services Introduction
11.15.4 JYMed Revenue in Formulation CDMO Services Business (2018-2023)
11.15.5 JYMed Recent Development
11.16 Chengdu Shengnuo Biotechnology
11.16.1 Chengdu Shengnuo Biotechnology Company Detail
11.16.2 Chengdu Shengnuo Biotechnology Business Overview
11.16.3 Chengdu Shengnuo Biotechnology Formulation CDMO Services Introduction
11.16.4 Chengdu Shengnuo Biotechnology Revenue in Formulation CDMO Services Business (2018-2023)
11.16.5 Chengdu Shengnuo Biotechnology Recent Development
11.17 Shanghai Soho-Yiming Pharmaceuticals
11.17.1 Shanghai Soho-Yiming Pharmaceuticals Company Detail
11.17.2 Shanghai Soho-Yiming Pharmaceuticals Business Overview
11.17.3 Shanghai Soho-Yiming Pharmaceuticals Formulation CDMO Services Introduction
11.17.4 Shanghai Soho-Yiming Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023)
11.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Development
11.18 Chinese Peptide Company
11.18.1 Chinese Peptide Company Company Detail
11.18.2 Chinese Peptide Company Business Overview
11.18.3 Chinese Peptide Company Formulation CDMO Services Introduction
11.18.4 Chinese Peptide Company Revenue in Formulation CDMO Services Business (2018-2023)
11.18.5 Chinese Peptide Company Recent Development
11.19 Ambio Pharmaceuticals
11.19.1 Ambio Pharmaceuticals Company Detail
11.19.2 Ambio Pharmaceuticals Business Overview
11.19.3 Ambio Pharmaceuticals Formulation CDMO Services Introduction
11.19.4 Ambio Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023)
11.19.5 Ambio Pharmaceuticals Recent Development
11.20 Zhejiang Peptites Biotech
11.20.1 Zhejiang Peptites Biotech Company Detail
11.20.2 Zhejiang Peptites Biotech Business Overview
11.20.3 Zhejiang Peptites Biotech Formulation CDMO Services Introduction
11.20.4 Zhejiang Peptites Biotech Revenue in Formulation CDMO Services Business (2018-2023)
11.20.5 Zhejiang Peptites Biotech Recent Development
11.21 STA Pharmaceutical
11.21.1 STA Pharmaceutical Company Detail
11.21.2 STA Pharmaceutical Business Overview
11.21.3 STA Pharmaceutical Formulation CDMO Services Introduction
11.21.4 STA Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.21.5 STA Pharmaceutical Recent Development
11.22 Zhejiang Langhua Pharmaceutical
11.22.1 Zhejiang Langhua Pharmaceutical Company Detail
11.22.2 Zhejiang Langhua Pharmaceutical Business Overview
11.22.3 Zhejiang Langhua Pharmaceutical Formulation CDMO Services Introduction
11.22.4 Zhejiang Langhua Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.22.5 Zhejiang Langhua Pharmaceutical Recent Development
11.23 Viva Biotech
11.23.1 Viva Biotech Company Detail
11.23.2 Viva Biotech Business Overview
11.23.3 Viva Biotech Formulation CDMO Services Introduction
11.23.4 Viva Biotech Revenue in Formulation CDMO Services Business (2018-2023)
11.23.5 Viva Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details